OncoTherapy Science,Inc. (4564): Share Price and Stock Information (including after-hours PTS)

According to the summary of OncoTherapy Science's earnings report, business revenue for the first quarter of the fiscal year ending March 2027 was ¥170.77 million, operating loss was ¥285.14 million, and net loss was ¥288.94 million, with losses continuing. Although the loss narrowed from the same quarter of the previous year, the company stated that there is significant doubt about the going-concern assumption and did not disclose its earnings forecast.

Performance over the past 12 quarters remains challenging, with net profit margin and operating profit margin staying negative. Although there has been some improvement due to a higher equity ratio, challenges remain regarding the company's stability.

The company has identified the following checkpoints for future performance: whole-genome analysis services that it continues to provide under contract, quality and information-management certifications such as CAP accreditation, progress in clinical development, target discovery through joint research, the start of development of new panel tests, and increased funding capacity through capital strengthening. At the same time, multiple risk factors have been identified, including the upfront burden of research and development expenses, fluctuations in the timing of revenue recognition under contracts, the risk of delays in clinical development, regulatory and error risks in clinical testing, dependence on sales to specific customers, the burden of managing confidential information, and dilution resulting from the exercise of stock acquisition rights.

External information cited as reference sources includes the earnings announcement date, a summary of the earnings report, a summary of performance trends, future checkpoints, and the company's funding situation.